DOCSLIB.ORG

Friday Afternoon May 4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Friday Afternoon May 4 FRIDAY—PM FRIDAY AFTERNOON MAY 4 F 1. BACK TO SCHOOL: A REVIEW OF FOUR FAST- 3:30 Defective Microglia-Neuronal Communication R MOVING FIELDS during Demyelinating Disease Correlates with I Altered Neurogenesis. A. Cardona, K. Church, Committee-Sponsored Session A. Mendiola, S. Cardona, D. Vanegas, C. Garcia, Sponsored by the AAI Program Committee D. Luera, S. Lira, E. Kokovay and C.-H. A. Lin. Univ. of Texas, San Antonio, Univ. of California, San FRI. 2:30 PM—ROOM 17AB Francisco, Icahn Sch. of Med., Mount Sinai and CHAIRS: E.M. Oltz, J.A. Punt Univ. of Texas Hlth. Sci. Ctr., San Antonio. (43.5) 3:45 T cell restricted TGF-βR3 (betaglycan) null mice This workshop intends to bring a broad audience up-to- develop exacerbated experimental autoimmune date on a few emerging or rapidly changing fields or areas encephalomyelitis (EAE) associated with of technological innovation. Expert lecturers will provide expanded generation of Th1 cells. S. Duesman, an overview of each trending topic with an emphasis on C. Ren, R. Chellappan, C. Sestero, R. Kesterson, communicating big picture concepts. P. De Sarno, G. Soldevila and C. Raman. Univ. of Alabama, Birmingham, Univ. of Montevallo and Natl. 2:30 Update on immunometabolism and how to fuel Autonomous Univ. of Mexico, Mexico. (43.6) immunity. J. Rathmell. Vanderbilt Univ. 4:00 IL7R regulates fetal tissue resident macrophage 3:00 Cell death in the immune system. D. Hildeman. development. G. Leung, T. McCann, C. Forsberg, Cincinnati Children’s Hosp. Med. Ctr. Anna Beaudin. Univ. of California, Merced and 3:30 Chromatin conformation and epigenetics of the antigen Univ. of California Santa Cruz. (43.7) receptor loci shape emerging immune repertoires. 4:15 IL-7 promotes naïve T cell motility and regulates T A. Feeney. Scripps Res. Inst. cell-dendritic cell contacts in the lymph node via 4:00 Defining essential features of epitope-specific T cell JAK/STAT signaling. J. R. Byrum, David Torres, receptor repertoires responding to pathogens and P. Mrass, S. Oruganti and J. Cannon. Univ. of tumors. P. Thomas. St. Jude Children’s Res. Hosp. New Mexico Sch. of Med. and Northern New Mexico Col. (43.8) 2. INFLUENCE OF CYTOKINES AND CHEMOKINES ON REGIONAL IMMUNITY 3. T LYMPHOCYTES AND TREGS: ACTIVATION, Block Symposium DIFFERENTIATION, AND TOLERANCE FRI. 2:30 PM—ROOM 16AB Block Symposium CHAIRS: G. Trevejo-Nunez, C. Raman FRI. 2:30 PM—ROOM 10AB 2:30 Glucocorticoids inhibit group 3 innate lymphocyte IL-22 CHAIRS: T. Burt, N. Singh production. L. Zenewicz, S. Seshadri and R. Pope. 2:30 Neurokinin 1 receptor-signaling sustains T-cell Univ. of Oklahoma Hlth. Sci. Ctr. (43.1) survival during thymus development and following 2:45 More than a decoy receptor? Interleukin 22 Binding T-cell activation in secondary lymphoid organs. Protein (IL-22BP) in bacterial pneumonia. G. Trevejo- A. Larregina, T. Sumpter, D. Rojas-Canales, Nunez, P. Castillo, K. Chen and J. Kolls. Univ. of O. Tkacheva, W. Shufesky, L. Falo and A. Morelli. Pittsburgh and Tulane Univ. Sch. of Med. (43.2) Univ. of Pittsburgh Sch. of Med. (47.15) 3:00 Exacerbation of intestinal IL-17 activity by mycoplasma 2:45 Subset-specific neurotransmitter receptor expression superantigen leads to increased HMGB1 and tunes T cell activation. K. Rosenberg and N. Singh. chemokines in the joints of autoimmune arthritis Univ. of Maryland, Baltimore. (47.22) mice. H-H. Mu and J. Tran. Univ. of Utah Sch. of Med. (43.3) 3:15 The damage signal IL-33 facilitates focal immune responses to Toxoplasma gondii in the brain. K. Still, J. Thompson, S. Batista, N. Hayes and T. Harris. Univ. of Virginia Sch. of Med. (43.4) 1 FRIDAY—PM 3:00 Glutamate receptors provide costimulatory signals 3:30 Immune regulation by glucocorticoids can be linked to improve T cell immune response. A. Shanker, to cell-lineage-specific transcriptional responses. M.T. de Aquino, T. Hodo and R. Uzhachenko. L. Franco, M. Gadkari, K. Howe, J. Sun, P. Kumar, Meharry Med. Col. Sch. of Med. and Vanderbilt Univ. L. Kardava, A. Biancotto, Z. Hu, I. Fraser, S. Moir, Sch. of Med. (47.24) R. Germain and J. Tsang. NIAID, NIH and NIH Clin. 3:15 Activation induced decrease and recovery of TCR Ctr. Pharmacy. (48.7) 2D affinity and bond lifetime. R. Andargachew, 3:45 Uracil DNA Glycosylase of Gammaherpesvirus alters E. Kolawole and B. Evavold. Emory Univ. and Univ. somatic hypermutation through error-free DNA of Utah Sch. of Med. (47.17) repair. Y. Mu, Q. Dong, M. Zelazowska, Z. Chen, 3:30 Tregs orchestrate antigen specific suppression via J. Plummer, L. Krug and K. McBride. The Univ. of stripping cognate peptide-MHCII from the DC Texas MD Anderson Cancer Ctr. and Stony Brook surface. B. Akkaya, M. Akkaya, Y. Oya, J. A. Souz, Univ. (48.12) A. Holstein, O. Kamenyeva, J. Kabat, D. Dorward, 4:00 Role of E3 ubiquitin ligase GRAIL in B cell activation D. Glass and E. Shevach. NIAID, NIH. (47.2) and tolerance. R. Nurieva, S. Bieerkehazhi, 3:45 Fetal naive T cells are primed for preferential T. Waseem, O. Hoang, A. Sahoo, A. Alekseev regulatory T cell differentiation through increased and E. Galkina. MD Anderson Cancer Ctr. and chromatin accessibility and expression at the Helios Eastern Virginia Med. Sch. (48.14) locus. M. Ng and T. Burt. Univ. of California, San 4:15 IRF4 regulates the rate of cell cycle during B Francisco. (47.12) cell differentiation. D. Patterson, C. Scharer 4:00 Transcriptional profiling of pathogen-specific CD4 and J. Boss. Emory Univ. Sch. of Med. (48.16) T cells reveals key events that regulate Th17 cell priming and differentiation. Y. Gao, K. Deason, 5. REGULATORY MECHANISMS OF INNATE A. Jain, I. Dozmorov, E. Wakeland and C. Pasare. IMMUNE RESPONSES Univ. of Texas Southwestern Med. Ctr. (47.7) 4:15 GDF15 and BMP4 co-regulate stress erythropoiesis Block Symposium and Treg induction to maintain erythroid homeostasis FRI. 2:30 PM—ROOM 18AB and resolve inflammation during infection. J. Fraser, A. Dey, S. Nettleford, L. Zhao, P. Hankey-Giblin, CHAIRS: M. Colonna, E. Amiel K. Prabhu, N. Xiong and R. Paulson. Pennsylvania 2:30 Regulatory circuits governing identity and function of State Univ. (47.14) human type 1 ILCs. P. Collins, M. Cella, S. Porter, M. Mccullen, M. Colonna and E. Oltz. Washington 4. B CELL BIOLOGY Univ. Sch. of Med. in St. Louis and Washington Univ. Block Symposium in St. Louis. (170.2) 2:45 Identification of Trim29 as a Key checkpoint inhibitor FRI. 2:30 PM—ROOM 19AB of natural killer cell functions. Y. Dou, J. Xing, CHAIRS: L-A. Garrett-Sinha, A. Satterthwaite X. Li and Z. Zhang. Houston Methodist Res. Inst.. (170.24) 2:30 NFAT1 nuclear translocation is impaired in murine 3:00 Ly49H-dependent IFNγ protein production by NK newborn B lymphocytes. J. Sakai, A. Coleman cells requires cytokine signaling that induces IFNγ and M. Akkoyunlu. CBER, FDA. (48.1) mRNA transcription. S. Piersma, M. Pak-Wittel 2:45 Differential regulation of B cell responses to acute and and W. Yokoyama. Washington Univ. in St. Louis. chronic infection by histone-modifying complexes. (170.9) K. Good-Jacobson, A. Di Pietro, C. Yiannis 3:15 Commensal Bacteria Suppress Vitamin A Metabolism and R. Farighi. Monash Univ., Australia. (48.2) in the Intestinal Epithelium to Modulate IL-22 Activity 3:00 IRF4 and IRF5 transcription factors exhibit shared in the Gut. M. Grizotte-Lake and S. Vaishnava. and distinct roles in regulating human B cell Brown Univ. (170.21) differentiation and function. T. Shih, S. De, B. Zhong 3:30 Transient Receptor Potential Ankyrin 1 Mediates and B. Barnes. Feinstein Inst. for Med. Res. and the Afferent Arm of the Inflammatory Reflex. Rutgers Univ., Pfizer, Inc. (48.3) H. Silverman, M. Addorisio, T. Tsaava, A. Stiegler, 3:15 AKT targets CSK to regulate proximal BCR signaling A. Kressel, C. Chin, M. Gunasekaran, V. Pavlov, in germinal center B cells. W. Luo, W. Hawse, S. Chavan and K. Tracey. Feinstein Inst. for Med. N. Trivedi, F. Weisel and M. Shlomchik. Univ. of Res. and Zucker Sch. of Med. at Hofstra/Northwell. Pittsburgh. (48.4) (170.27) 2 FRIDAY—PM 3:45 Sympathetic neural control of inflammation by ADRB2- 3:45 In situ vaccination improves efficacy of PD-1 blockade mediated IL-10 secretion. D. Agac, L. Estrada in unresponsive lymphoma tumors through induction and J. Farrar. Univ. of Texas Southwestern Med. of a highly efficient cross-presenting dendritic Ctr. and St. Jude Children’s Res. Hosp. (170.22) cell subset expressing TLR3. L. Hammerich, 4:00 Nitric oxide dictates the reprogramming of carbon flux M. Dhainaut, T. Keler, T. Davis, A. Salazar, during M1 macrophage polarization. E. Palmieri, B. Brown and J. Brody. Icahn Sch. of Med., Mount W. Baseler, L. Davies, M. Gonzalez-Cotto, Sinai, Celldex Therapeut. and Oncovir, Inc. (56.17) F 4:00 Systemic dysregulation of antigen cross-presenting B. Ghesquiere, T. Fan, A. Lane, D. Wink R and D. McVicar. NCI, NIH, Univ. of Leuven, Belgium dendritic cells occurs early in preinvasive pancreatic and Univ. of Kentucky. (170.18) neoplasia and is reversed by CD40 agonism. J. Lin I 4:15 The Role of Glycogen Metabolism in Glycolytic and R. Vonderheide. Perelman Sch. of Med.,Univ. Reprogramming Required for Dendritic Cell Immune of Pennsylvania. (56.18) Responses. E. Amiel and P. Thwe. Univ. of Vermont. 4:15 Cell death-inducing reagents activate cancer (170.6) immune surveillance via inducing Interleukin-17D in macrophages. R. Seelige and J. Bui. Univ. of 6. MACROPHAGES AND MYELOID AND California, San Diego. (56.23) DENDRITIC CELLS IN TUMOR IMMUNITY AND IMMUNOTHERAPY 7.
Load more

Recommended publications
  • Ulcerative Colitis
    +44 20 8123 2220 [email protected] Ulcerative Colitis - Pipeline Review, H1 2020 https://marketpublishers.com/r/U44188EFA0EEN.html Date: April 2020 Pages: 671 Price: US$ 2,000.00 (Single User License) ID: U44188EFA0EEN Abstracts Ulcerative Colitis - Pipeline Review, H1 2020 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape. Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids. REPORT HIGHLIGHTS Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected] involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects.
    [Show full text]
  • Kansas City Regional Life Sciences Industry Census 2018 Executive Summary
    Kansas City Regional Life Sciences Industry Census 2018 Executive Summary ................................................................................................................... 4 Background ................................................................................................................................ 7 Methodology .............................................................................................................................. 8 Industry Presence, Overview & Analysis ...................................................................................12 Introduction ...........................................................................................................................12 Presence and Overview ........................................................................................................13 Regional Developments 2016-2018 ...................................................................................13 Life Sciences Capital .........................................................................................................21 Incubators, Accelerators, and New Business Facilities.......................................................25 Universities ........................................................................................................................28 Hospitals ............................................................................................................................32 Analysis .................................................................................................................................33
    [Show full text]
  • Life Science District
    Fitzsimons Life Science District a great place to raise an idea Located in Aurora, Colorado, it’s one of the largest bioscience developments in the country, a place where there’s plenty of room to grow an idea from discovery to market viability. Whether you start in the bioscience incubator or move into a state-of-the art lab facility, everything you need is close at hand. A cluster of talent and resources is available to you, including direct access to the more than 80 core laboratories at the University of Colorado Anschutz Medical Campus – all just steps away. Features throughout the district, such as parks and conference facilities, are designed to inspire collaboration. And a nearby mix of shops, restaurants and homes let your people thrive right along with your ideas. For leasing and land purchase opportunities at the Colorado Science + Technology Park, within the Fitzsimons Life Science District, call 720-941-7100. Join the conversation at FitzScience.com FIT 110352 Brand Ad_M.indd 1 3/23/11 1:32 PM Improve the health of your business. Collaborations between bioscience 227 acres of state-of-the-art patient successful Colorado companies such companies and faculty researchers at care, research and education, the as Myogen/ Gilead Sciences Colorado, the University of Colorado Anschutz Anschutz Medical Campus provides GlobeImmune, ARCA, and ApopLogic Medical Campus are flourishing. unique opportunities for business Pharmaceuticals. And with Denver Which means the opportunities for development. The University’s International Airport being only 15 improvement—in the health of Technology Transfer o ce, ranked minutes away, access to both coasts Coloradoans and in the health of among the top 20 universities for takes only a few hours.
    [Show full text]
  • Ensuring U.S. Biopharmaceutical Competitiveness
    Ensuring U.S. Biopharmaceutical Competitiveness STEPHEN EZELL | JULY 2020 If the United States is serious about maintaining its leadership in biopharmaceuticals, then it’s time for policymakers to articulate and embrace a robust sectoral competitiveness strategy. KEY TAKEAWAYS ▪ The biopharmaceutical industry makes important contributions to the U.S. economy, including employing over 500,000 workers making 1.4 times the U.S. earnings average. ▪ The United States leads the world on most indices of R&D investment and innovation. From 2004 to 2018, U.S.-headquartered firms produced almost twice as many new drugs as did firms in Europe, and 3 to 4 times as many as Japan. ▪ Despite U.S. strengths in biopharmaceutical R&D and innovation, manufacturing has dropped. From 2009 to 2018, real value-added output in pharmaceutical and medicines manufacturing fell by nearly one-third. ▪ Partly as a consequence, the U.S. trade balance in pharmaceuticals has grown from a deficit of $16 billion in 2010 to a deficit of $77 billion in 2019. ▪ Calls for reshoring more biopharmaceutical manufacturing should distinguish between mature manufacturing processes and those still evolving, as in continuous process biomanufacturing, where U.S.-based production can enjoy unique strengths. ▪ America must continually bolster its biopharmaceutical leadership position, especially as China implements ever-more aggressive policies to improve their life-sciences competitiveness, not only in production but also in innovation. ▪ To support the sector, policymakers should focus on: 1) maintaining strengths, including in pricing, tech transfer, and intellectual property; 2) spurring domestic innovation; 3) spurring increased domestic production; and 4) combatting foreign mercantilism.
    [Show full text]
  • An Emerging National Resource for Clinical Research and Your Healthcare Partner in Personalized Medicine Innovation
    An Exclusive Membership Look into Colorado To visualize improving the world around us Fisher Scientifi c, part of Thermo Fisher Scientifi c, the world leader in serving science, is pleased to have the opportunity to partner with the Colorado BioScience Association and act as primary supplier of laboratory products, safety supplies, equipment, chemicals, reagents and a host of services. Fisher Scientifi c understands today’s challenging environment and has capabilities that align with CBSA’s strategic goals going beyond just providing products to o ering Colorado BioScience Association members access to customized programs to fi t their specifi c needs from start-up to scale-up. 1.800.766.7000 • Fax: 1.800.926.1166 • www.fi shersci.com 2 BIOSCIENCECOLORADO 2014-2015 Litho in U.S.A. 13_0280 JJ/KJ COLOR ADO 2014-2015 Drawing People & Data Together to Benefit Human Health 10 22 26 14 6 CONTENTS 06 Mobile Health in Colorado: Where “Big Data” Sparks Big Ideas 10 Biodesix Harnesses Machine Learning and Analytics to Tackle Multivariate Diagnostics 14 Bioscience in Colorado Continues to Shine with U.S. Senator Michael Bennet 16 Color ado Life Science Assets: A Sophisticated Repertoire of Clinical-Stage Therapeutic, Device and Diagnostic Products 22 Webb-Waring Biomedical Research Program 26 F ound in Translation: Rocky Mountain Lions Eye Institute Translational Research Programs Focus on Innovative Treatment of Eye Diseases 30 Connecting the Dots: Tech Transfer Offices Connect Research and Marketplace to Stimulate the State's Economy 33 Colorado by the Numbers: Financing and Acquisitions 36 Grant Programs: Innovation Engines 48 Colorado Bioscience Industry Directory 2014-2015 BIOSCIENCECOLORADO 3 We Know Workforce elcome to the Colorado BioScience Association’s eleventh anniversary edition of Bioscience Colorado.
    [Show full text]
  • Biotecnología Y Desarrollo
    Documento de proyecto Biotecnología y desarrollo Roberto Bisang Mercedes Campi Verónica Cesa Comisión Económica para América Latina y el Caribe (CEPAL) Este documento fue preparado por Roberto Bisang y Verónica Cesa, consultores, y Mercedes Campi, asistente de investigación de la Oficina de la Comisión Económica para América Latina y el Caribe (CEPAL) en Buenos Aires a pedido de la Oficina de la Secretaría Ejecutiva de la CEPAL. Las opiniones expresadas en este documento, que no ha sido sometido a revisión editorial, son de exclusiva responsabilidad de los autores y pueden no coincidir con las de la Organización. Publicación de las Naciones Unidas LC/W.234 LC/BUE/W.35 Copyright © Naciones Unidas, marzo del 2009. Todos los derechos reservados Impreso en Naciones Unidas, Santiago de Chile La autorización para reproducir total o parcialmente esta obra debe solicitarse al Secretario de la Junta de Publicaciones, Sede de las Naciones Unidas, Nueva York, N. Y. 10017, Estados Unidos. Los Estados miembros y sus instituciones gubernamentales pueden reproducir esta obra sin autorización previa. Sólo se les solicita que mencionen la fuente e informen a las Naciones Unidas de tal reproducción. CEPAL – Colección Documentos de proyectos Biotecnología y desarrollo Índice Resumen .................................................................................................................................. 5 I. Introducción ............................................................................................................................
    [Show full text]
  • Framing the Genetic Engineering Debate: an Examination of Frames and Sources in Local Newspaper Reporting
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 8-2005 Framing the Genetic Engineering Debate: An Examination of Frames and Sources in Local Newspaper Reporting Catherine Emma Crawley University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Communication Commons Recommended Citation Crawley, Catherine Emma, "Framing the Genetic Engineering Debate: An Examination of Frames and Sources in Local Newspaper Reporting. " PhD diss., University of Tennessee, 2005. https://trace.tennessee.edu/utk_graddiss/1907 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by Catherine Emma Crawley entitled "Framing the Genetic Engineering Debate: An Examination of Frames and Sources in Local Newspaper Reporting." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the equirr ements for the degree of Doctor of Philosophy, with a major in Communication and Information. Edward Caudill, Major Professor We have read this dissertation and recommend its acceptance: Paul Ashdown, Suzanne
    [Show full text]
  • Warhawk Therapeutic Technologies
    New Product Assessment Warhawk Therapeutic Technologies Therapeutic proteins are proteins that are either engineered in a laboratory or extracted from human or animal cells for pharmaceutical use as the active substance in a drug. Most of these therapeutic proteins are recombinant human proteins. They are manufactured in non-human mammalian cell lines that have been designed to express a specific human genetic sequence. The majority of these biopharmaceuticals are recombinant therapeutic proteins administered by injection. Once injected into the body, the proteins are broken down by enzymes and cellular activity in the bloodstream and are filtered out of the blood by the body’s organs. Thus, patients must receive frequent injections to maintain effective therapeutic levels of protein in the body. Therapeutic proteins are used for treatment and prevention of diseases and disorders in the human body. For example diabetes, arthritis, infections, heart attacks, and cancers can all be treated through the use of these proteins. There are several production technologies in this industry aimed at maximizing the production yields of these proteins. Current methods of production only yield 10 percent to 20 percent of the therapeutic proteins. However, Warhawk Therapeutic Technologies’ production technology is capable of yielding XX – XX percent which, in turn will reduce production costs and initial capital investments on manufacturing facilities. Additionally, the protein folding process employed by Warhawk Therapeutic Technologies does not require the use of strong chemical reagents or special equipment. The following report includes a review of competition, a preliminary patent search, a sample of market feedback, and an investigation into trends that may affect the market for the Warhawk Therapeutic Technologies protein folding system.
    [Show full text]
  • Biotechnology Training Retreat
    3333 Eighteenth Annual Biotechnology Training Retreat Saturday, March 29, 2008 Christian Brothers Retreat & Conference Center Napa, CA Eighteenth Annual Biotechnology Training Retreat Saturday, April 4, 2009 Christian Brothers Retreat & Conference Center Napa, CA Co-sponsored by: NIH Training Program in Biomolecular Technology (NIH-1-T32-GM08799) UC Davis Designated Emphasis in Biotechnology Graduate Program (DEB) UC Davis Biotechnology Program 2 Table of Contents Welcome .............................................................................................................................. 4 NIH Training Program in Biomolecular Technology ................................................................. 6 Designated Emphasis in Biotechnology, UC Davis ............................................................. 7 UC Davis Biotechnology Program ...................................................................................... 8 Retreat Agenda .................................................................................................................... 9 2009 Poster Titles ............................................................................................................. 10 Oral Presentation Abstracts ............................................................................................... 14 Bioethics ........................................................................................................................... 35 Poster Abstracts ................................................................................................................
    [Show full text]
  • Bridging the Gap: from Discovery to Commercialization
    Bridging the Gap: from Discovery to Commercialization Bioscience Discovery Visualizing Evaluation the Gap Grant Program page 6 page 24 Colorado by Directory the Numbers: of Bioscience 2011 update Companies and page 11 Resources page 42 Fitzsimons Life Science District a great place to raise an idea Located in Aurora, Colorado, it’s one of the largest bioscience developments in the country, a place where there’s plenty of room to grow an idea from discovery to market viability. Whether you start in the bioscience incubator or move into a state-of-the art lab facility, everything you need is close at hand. A cluster of talent and resources is available to you, including direct access to the more than 80 core laboratories at the University of Colorado Anschutz Medical Campus – all just steps away. Features throughout the district, such as parks and conference facilities, are designed to inspire collaboration. And a nearby mix of shops, restaurants and homes let your people thrive right along with your ideas. For leasing and land purchase opportunities at the Colorado Science + Technology Park, within the Fitzsimons Life Science District, call 720-941-7100. Join the conversation at FitzScience.com FIT 110352 Brand Ad_M.indd 1 3/23/11 1:32 PM Improve the health of your business. Collaborations between bioscience 227 acres of state-of-the-art patient successful Colorado companies such companies and faculty researchers at care, research and education, the as Myogen/ Gilead Sciences Colorado, the University of Colorado Anschutz Anschutz Medical Campus provides GlobeImmune, ARCA, and ApopLogic Medical Campus are flourishing.
    [Show full text]
  • Science Industry Public Policy Economic Development the Future
    2013-2014 Colorado by the Numbers Science Bioscience Industry Discovery Public Policy Evaluation Grant Economic Development Program The Future An Exclusive Membership Look into Colorado To visualize improving the world around us Fisher Scientifi c, part of Thermo Fisher Scientifi c, the world leader in serving science, is pleased to have the opportunity to partner with the Colorado BioScience Association and act as primary supplier of laboratory products, safety supplies, equipment, chemicals, reagents and a host of services. Fisher Scientifi c understands today’s challenging environment and has capabilities that align with CBSA’s strategic goals going beyond just providing products to off ering Colorado BioScience Association members access to customized programs to fi t their specifi c needs from start-up to scale-up. 1.800.766.7000 • Fax: 1.800.926.1166 • www.fi shersci.com Litho in U.S.A. 13_0280 JJ/KJ 13_0280 Colorado BioScience Ad.indd 1 2/21/2013 12:39:53 PM TABLE OF CONTENTS Welcome to the Colorado BioScience Association’s tenth anniversary edition of Bioscience Colorado, 10 years of supporting the the state’s only in-depth bioscience industry in Colorado guide and directory to the bioscience industry. In honor Then, Now, The Future of our 10 years supporting the bioscience industry in Colorado, we will be celebrating our successful history and looking ahead to the future. 5 16 Over the past decade, the Association has The Science The Economic grown from a small startup enterprise to a mature A Decade of Dramatic Development and successful organization. This publication Developments: Building the Colorado is an integral part of the Association’s mission Bioscience in Colorado Bioscience Industry to support the Colorado bioscience community Cluster: through advocacy, resources and advancement of opportunities for collaboration.
    [Show full text]
  • Directory Sequel Ventures of Colorado Sierra Neuropharmaceuticals Bioscience Taligen Therapeutics Companies Page 6
    The Money Game Hear From Barofold ARCA Biopharma Directory Sequel Ventures of Colorado Sierra Neuropharmaceuticals Bioscience Taligen Therapeutics Companies Page 6 & Resources Page 38 Colorado’s Bioscience Industry By the Numbers Page 12 Colorado Invests In the Biosciences Page 33 DPMPSBEP TDJFODF $PMMBCPSBUJPOCSFFETJOOPWBUJPO UFDIOPMPHZ QBSL BU¾U[TJNPOT $PMMBCPSBUJPOCSFFETJOOPWBUJPO°BOE JOOPWBUJPOCFDPNFTTPMVUJPOTBOEDVSFT 5IF$PMPSBEP4DJFODF 5FDIOPMPHZ1BSL BU'JU[TJNPOTJTQFSGFDUMZQPTJUJPOFEUP DPMMBCPSBUFXJUIUIFBEKBDFOU6OJWFSTJUZ PG$PMPSBEPµT"OTDIVU[.FEJDBM$BNQVT BOE5IF$IJMESFOµT)PTQJUBM*OGBDU DPMMBCPSBUJPO DPPQFSBUJPOBOETDJFOUJ¾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µT)PTQJUBM 5)&$)*-%3&/µ4)041*5"- JTEF¾OJUFMZUIFDBUBMZTUGPSUIJTTVDDFTTGVM "/%3&4&"3$)$&/5&3 TDJFOUJ¾DGPSNVMB 5IF$PMPSBEP4DJFODF 5FDIOPMPHZ1BSLBU 'JU[TJNPOTJTBQMBDFXIFSFUIFCFTUBOEUIF CSJHIUFTUDPNFUPHFUIFSUPUBLFJEFBTGSPN CFODIUPCFETJEFBQMBDFXIFSFDSFBUJWJUZ BOEDPMMBCPSBUJPOSFBDIDSJUJDBMNBTT XXX'JU[4DJFODFDPN cstp-f ad_f.indd 1 3/21/08 10:15:13 AM #JPTDJFODF$PMPSBEP.BHB[JOF QBHF4QSFBEY CMFFE $PMPSBEP4DJFODF
    [Show full text]